Royalty Report: Drugs, Cancer, Antibody – Collection: 296181

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Antibody
  • Immune
  • Drug Discovery
  • Disease
  • Pharmaceuticals
  • Diagnostic
  • Therapeutic
  • Vaccine
  • Dermatology
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 296181

License Grant
The Parties have a collaboration and exclusive license agreement.  Under the terms of the amended agreement, Licensor granted an exclusive, sub-licensable worldwide license to research, develop, manufacture, market and sell products based on our proprietary technology.
The November amendment adds an additional dual-reactive antibody product candidate.
License Property
Licensor granted exclusive rights to three monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033) and PD-1 (TSR-042) and a bispecific antibody product candidates targeting PD-1 and LAG-3.

The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.

Field of Use
The field of use is for the discovery, generation and optimization of certain specified immunotherapy antibodies.  With the amendment, the field is for performing initial discovery and development of therapeutic antibodies with the goal of generating immunotherapy antibodies for use in the treatment of cancer.

IPSCIO Record ID: 184504

License Grant
The amendment to the terms of the original collaboration agreement, among other things, converts the GITR and OX40 programs from profit-share to royalty-bearing programs.  In addition, the profit-share programs relating to two undisclosed targets were removed from the collaboration, with one reverting to Licensee and one to Licensor (the latter being the TIGIT antibody program).  The remaining three royalty-bearing programs in the collaboration targeting TIM-3, LAG-3 and one undisclosed target remain unchanged, and there are no more profit-share programs under the collaboration.

The original agreement entered into a broad, global alliance with the parties to discover, develop and commercialize novel immuno-therapeutics using the antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, was expanded by adding three novel undisclosed CPM targets.

License Property
The Licensor is a clinical-stage immuno-oncology (I-O) company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer.

GITR is an immune checkpoint agonist, one of a class of receptors that amplify the immune system’s response to cancer. GITR (glucocorticoid-induced TNFR-related protein) is a receptor expressed on select populations of T cells. Activation of GITR leads to a more powerful anti-tumor inflammatory response, increased production of inflammatory signaling molecules and increased resistance to immunosuppression.

OX40 (also known as CD134 and TNFRSF4), a member of the TNFR super-family, is an immune-response-enhancing receptor found on activated T cells. OX40 promotes proliferation of these activated T cells and prevents the immunosuppressive activity of inhibitory T cells. We believe that antibodies that activate OX40 may help increase immune system activity through both of these mechanisms. Furthermore, OX40 antibodies have the potential to work alone or in combination with other therapeutics. Combining with another agonist checkpoint antibody, which provides different, yet complementary signaling attributes may further augment anti-tumor responses.

Field of Use
Checkpoint antibodies effect the immune system, and are now being used in cancer treatment.

IPSCIO Record ID: 307594

License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.

The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.

Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.

Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.

Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.

IPSCIO Record ID: 135993

License Grant
Licensor of the Netherlands entered into a Collaboration and License Agreement and Share Subscription Agreement with the Licensee.  Under the terms of the Collaboration Agreement, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing the Licensor’s proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, including two of the Licensor’s current preclinical immuno-oncology discovery programs. For one of the current preclinical programs, Program 1, the Licensor retains the exclusive right to develop and commercialize products and product candidates in the United States, while Licensee has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States.  The Licensor has the option to co-fund development of products arising from two other programs in exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of detailing activities in the United States for one of such programs. Should Program 1 fail to successfully complete IND-enabling toxicology studies, the Licensor would be granted an additional option to co-fund development of a program in exchange for a share of profits in the United States.  The Licensor retains the rights to its bispecific technology platform as well as clinical and pre-clinical candidates and future programs emerging from the Company’s platform that are outside the scope of the Collaboration Agreement.
License Property
The collaboration encompasses up to 11 independent programs, including two of the Licensor’s current preclinical immuno-oncology discovery programs, with respect to the research, discovery and development of bispecific antibodies utilizing the Licensor’s proprietary bispecific technology platform.
A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen.
Field of Use
This agreement applies to the drug development industry.

IPSCIO Record ID: 27803

License Grant
Licensor grants the Swiss Licensee, an exclusive, non-transferable  license or sublicense, as applicable, under the Licensor IP to Develop, Manufacture and Commercialize Licensed Antibodies and Products in the Territory and in the Field.

The Licensor and the Licensee formed a global alliance focused on novel immuno-therapeutics using the Licensor's proprietary Retrocyte Displayâ„¢ antibody discovery platform. The collaboration is initially focused on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3 and TIM-3.

License Property
The Licensor is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants.

LAG-3 is a checkpoint protein expressed on the surface of certain cells of the immune system. LAG-3 (lymphocyte-activation gene 3) modulates signaling between immune cells and their targets. When LAG-3 is activated, the immune response is suppressed. Antibodies that block LAG-3 can block this inhibitory signal, thereby boosting the immune system’s response against cancer cells. LAG-3 acts synergistically with other checkpoint modulators. This suggests antibodies against LAG-3 may be valuable as combination therapies.

TIM-3 is a checkpoint receptor found on certain immune cells. TIM-3 stands for T-cell immunoglobulin and mucin domain-3. To prevent hyperactivation, natural ligands binding to TIM-3 reduce the activity of these immune cells. In some types of cancer, T cells express elevated levels of TIM-3, which results in excessive immune suppression. Blocking TIM-3 could stimulate immune responses and promote immune-mediated clearing of cancer cells. TIM-3 antibodies may have a role as a monotherapy and hold great potential in combination therapy, since they may help overcome resistance that patients may develop against other therapeutics.

[U.S. Patent Application Serial No. 62/004,071, filed May 28, 2014, entitled 'Anti-GITR Antibodies and Methods of Use Thereof.']
Field of Use
The Parties are interested in forming an alliance whose goal is to discover, develop and commercialize a robust portfolio of products to address hematologic and oncologic diseases or conditions.

Checkpoint antibodies effect the immune system, and are now being used in cancer treatment.

The Field means any use of Antibodies for the treatment, control, mitigation, prevention or cure of any or all Indications in humans or animals in the Hematology Field and the Oncology Field

IPSCIO Record ID: 336288

License Grant
Licensor granted Licensee an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term.
License Property
DART platform is a platform that is a designed antibody-based product candidate that have the potential to improve on standard treatments by having one or more of the following attributes (1) multiple specificities; (2) increased abilities to interact with the bodys immune system to fight tumors; (3) capacity to bind more avidly to antigen targets (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments.

DART platform enables us to design multi-specific molecules that seek to exploit different mechanisms.

Field of Use
Field of use is for the treatment of complex biology of cancer.  DART platform is used to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies.

IPSCIO Record ID: 144995

License Grant
Licensor grants an exclusive license in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Know-How, to make, have made, use and sell Products in the Field.  During the research term, the Licensor shall not perform any research or development work in the field with any other party.
License Property
L6 Antibodies shall mean those certain Program Antibodies that are murine or chimeric antibodies and are specifically reactive immunologically with the L6 antigen, such L6 antigen having characteristics substantially  described, as amended, supplemented or modified from time to time.
Field of Use
The Field shall mean the in vivo diagnosis or treatment of solid tumors in humans through the use of one or more antibodies.

The Diagnostic Product shall mean a diagnostic product, containing one or more Program Antibodies, for use in the in vivo detection of solid tumors in humans.

The Therapeutic Product shall mean the final dosage formulation of a product incorporating pharmaceutical compositions containing a Program Antibody for use in the treatment of solid tumors in humans, regardless of the route of administration. Each different chemical formulation of a Therapeutic Product containing the same one or more Program Antibodies but no additional antibodies, except different formulations for use in the treatment of the same indication in the Field by different routes of administration, shall constitute a different Therapeutic Product.

IPSCIO Record ID: 368652

License Grant
University of the United Kingdom grants
—   an exclusive non-transferable, except as a license in the Field under the Patents, with the right to sublicense, to research, develop, manufacture, have manufactured, use, import, offer for sale and sell Licensed Products in the Territory
—  an exclusive license in the Field to use the Know-How, with the right to sublicense, to research, develop, manufacture, have manufactured, use, import, offer for sale and sell Licensed Products in the Territory;
—  an exclusive license in the Field to use the Materials, solely for research and development purposes. For the avoidance of doubt Licensee shall not humanize any of the Materials nor administer the Materials, or any substances contacted with the Materials, to human subjects.

Licensee shall not grant sub-licenses to any Tobacco Party.

License Property
The University has determined that agonistic anti-mouse CD27 antibodies were unexpectedly potent at triggering T-cell expansion and identified the potential application of using such antibodies as vaccines for the treatment of disorders that may benefit from immune stimulation.

University has a patent application for Human Immune Therapies Using a CD27 Agonist Alone or in Combination with Other Immune Modulators.

University also has generated an agonistic anti-mouse CD27 mAb (clone AT124-1) and a selection of mouse anti-human CD27 MAb, included in the Materials.

Materials means agonistic anti-mouse CD27 mAb {clone AT124-1} and agonistic mouse anti-human C027 mAbs {clones AT133·2, AT133-4, AT133·5, AT133·6, AT133-7, AT133·11 and AT133-14) and any derivatives thereof generated by Licensee, its Affiliates or sub-licensees.

The Know-How includes Know~how in developing functional agonistic human mAb to CD27.

Field of Use
The patent and know-how license agreement is to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers.   In pre-clinical models, antibodies to CD27 alone have been shown to mediate anti-tumor effects, and may be particularly effective in combination with other immunotherapies. CD27 is a critical molecule in the activation pathway of lymphocytes. It is downstream from CD40, and may provide a novel way to regulate the immune responses. Engaging CD27 with the appropriate monoclonal antibody has proven highly effective at promoting anti-cancer immunity in mouse models. We are currently evaluating new human monoclonal antibodies in pre-clinical models.

The Field means all therapeutic or prophylactic uses. including uses as adjuvants or vaccines, in the Territory of agonistic anti-CD27 antibodies, alone or in combination with any other pharmaceutical agent, other than the Universitys Field.

Universitys field means all therapeutic or prophylactic uses, including uses as adjuvants or vaccines, in the Territory of agonistic anti-CD27 antibodies in combination with the Universitys proprietary anti-human CD40 ChiLob7.4 antibody and derivatives thereof where such use includes the in vivo administration of such anti-CD27 antibody and such anti-human CD40 ChiLob7.4 antibody to a mammal or the in vitro use of such anti-C027 antibody and such anti-human CD40 Ch1Lob7.4 antibody, wherein the two antibodies must be administered together as an approved therapeutic combination regimen.

IPSCIO Record ID: 250946

License Grant
The Parties will collaborate on the discovery of monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways using the Canadian Licensors antibody discovery capabilities and its proprietary AzymetricTM and EFECTTM platforms.  The Danish Licensee will have exclusive rights to develop and commercialize two bispecific antibody candidates for application in dermatology indications and the Canadian Licensor will retain the rights to develop antibodies targeting cytokine-receptor pathways in any non-dermatology indications.
License Property
The Danish Licensee granted the Canadian Licensor a non-exclusive, worldwide, royalty-free research and development license allowing the Licensee to perform certain research and development activities and a non-exclusive license to use certain intellectual property to develop and commercialize antibodies targeting cytokine-receptor pathways in any non-dermatology indications.
Field of Use
The Danish Licensee will commercialize the Antibodies for dermatology applications.

IPSCIO Record ID: 289177

License Grant
With this agreement, Licensee wishes Licensor to apply its technology and know-how to genetically engineer a Single-Chain Antibody.

The Licensor of Scotland agrees to grant the German Licensee under the patent rights a non-exclusive world-wide licence to the extent necessary to commercialise the Deimmunised antibody and/or the deliverables in the field.

Licensor grants for each specific Deimmunised antibody a non-exclusive licence under the patent rights to the extent necessary for worldwide commercialisation of the Deimmunised antibody derived from the specific Single-Chain Antibody sequence.

License Property
Licensor has certain proprietary technology, materials and know-how in genetic engineering of biological materials, including single-chain antibodies, relating to removal of potentially immunogenic sequences, from the variable regions of antibodies, or Delmmunisation to produce an antibody for therapeutic and/or in vivo diagnostic purposes.

Licensee is the owner of a cDNA which encodes a Single-Chain Antibody which binds to a specific antigen.

Licensor patent rights shall mean all patent applications and granted patents relevant to Deimmunization Technology.

Deimmunised antibody shall mean all genetically engineered variant(s) of the single-chain antibody  arising from the research.

Deimmunization technology shall mean the technical process applied by Licensor to generate Deimmunised antibody as outlined in the research program.

DeImmunisation increases the clinical potential of antibody and protein therapeutics by eliminating/reducing the T-cell response caused when the therapeutic molecule is recognised as foreign by the patient's immune system. The technology is based on ‘peptide threading' and works by identifying potential T-cell epitopes on the therapeutic antibody or protein. T-cell epitopes are sites on the therapeutic molecule which can bind to MHC class II, triggering a T-cell mediated immune response. Once this potentially immunogenic region of the antibody is identified, it is removed from the molecule by single amino acid substitutions, thus eliminating/reducing the therapeutic antibody or protein's immunogenicity and increasing its safety. This can be done without compromise to efficacy.

Field of Use
The field shall mean the field of human therapy and human in vivo and in vitro diagnostics limited to the Single-Chain Antibody.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.